24Feb 2025
DESTINY-Breast04: Expanding HER2-Low Targeting in Breast Cancer

DESTINY-Breast04: Expanding HER2-Low Targeting in Breast Cancer

HER2-low breast cancer benefits from targeted therapy! The DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan effectively treats tumors without HER2 overexpression. However, semiquantitative IHC assays lack precision in detecting low HER2 levels, making the exclusion of IHC 0 patients from the trial questionable. The ASCO-CAP panel recognizes the need for clearer IHC 1+ vs. IHC 0 distinctions to refine treatment eligibility and improve patient outcomes.

  • #oncology

Like

Save

Share